NEURODEVELOPMENTAL OUTCOMES OF SINGLETON CONCEIVED FROM FRESH AND FROZEN EMBRYO TRANSFER COMPARED WITH NATURALLY CONCEIVED

NCT ID: NCT04772872

Last Updated: 2021-02-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

186 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-02-01

Study Completion Date

2022-02-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aimed to: detect difference in neurobehavior, maturity, Apgar score and birth weight of singleton conceived from fresh and frozen embryo transfer and naturally conceived.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The use of ART has increased significantly during the past decades with more than 390000 children born worldwide annually and the total number of ART children now exceeding 7 million (Adamson et al., 2018). ART is associated with an increased risk of perinatal complications, including preterm birth (PTB) and small for gestational age (SGA) (Pandey et al., 2012 and Pinborg et al., 2013).

When mothers had been received ovarian stimulation in ART, multiple follicles and corpora lutea are produced, which produce supraphysiologic serum levels of multiple hormones and other factors, including estradiol, progesterone, and vascular endothelial growth factor (VEGF). This non physiological hormonal milieu affects both the endometrium and the embryo, potentially resulting in altered growth of the developing fetus. There was a serious effect of the supraphysiologic hormonal environment on pregnancy outcomes. (Imudia et al., 2012).

Neonates born after an IVF/ICSI procedure have an increased risk of various developmental problems, neurological disabilities, impairments or handicap, especially the cerebral palsy (CP) (Strömberg et al., 2002 and Squires and Kaplan, 2007).The increased risk of prematurity and smaller birth weight after an ART procedure required regular periodic screening and careful developmental follow-up of these children. (Boulet et al., 2008).

Singleton born after an IVF procedure were more likely to need habilitation treatment and had increased risk of developing neurological problems, especially cerebral palsy (CP), suspicion for a delay in their development. (Strömberg et al., 2002) Children born after an IVF procedure had three times higher presence of CP compared to the children from the general population and the risk of suspicion for a delay in their development was four times higher in children born after an IVF procedure than in the naturally conceived. (Strömberg et al., 2002). There is evidence of associations among the ART procedure and the developmental delay (Hvidtjørn et al., 2009).

The lack of early examination of neonates׳s neurobehavior conceived from ICSI/IVF may be led to developmental delay in these neonates. Early detection of neurobehavior deviation is essential for effective control of this potentially debilitating morbidity. As there is no available data about neurobehavior of Egyptian neonates conceived from frozen and fresh embryo transfer so there is an arising need to address this gap of knowledge.

Thus, to overcome previous limitation, the current study aimed to evaluate neurobehavior of singletons conceived from fresh and frozen embryo transfer compared with naturally conceived and screening for identify need for early intervention and developmental follow up to prevent worsening and progression of dysfunctions.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Singeleton Conceived Fresh and Frozen Embryo Transfer (ICSI/IVF), Naturally Conceived

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group A:Naturally conceived singleton

* Neonatal neurobehavior will be measured by Brazelton neonatal behavior assessment scale.
* Neonatal maturity will be represented by the variance of estimated gestational age that determined by new Ballard score.
* Apgar score will be represented by the variance of degree of scores.
* Birth weight will be measured in grams.

Assessment by Brazelton neonatal behavior for group A,Band C

Intervention Type OTHER

* Neonatal neurobehavior will be measured by Brazelton neonatal behavior assessment scale.
* Neonatal maturity will be represented by the variance of estimated gestational age that determined by new Ballard score.
* Apgar score will be represented by the variance of degree of scores.
* Birth weight will be measured in grams.

Group B: Singleton conceived from fresh embryo transfer(IVF/ICSI)

* Neonatal neurobehavior will be measured by Brazelton neonatal behavior assessment scale.
* Neonatal maturity will be represented by the variance of estimated gestational age that determined by new Ballard score.
* Apgar score will be represented by the variance of degree of scores.
* Birth weight will be measured in grams.

Assessment by Brazelton neonatal behavior for group A,Band C

Intervention Type OTHER

* Neonatal neurobehavior will be measured by Brazelton neonatal behavior assessment scale.
* Neonatal maturity will be represented by the variance of estimated gestational age that determined by new Ballard score.
* Apgar score will be represented by the variance of degree of scores.
* Birth weight will be measured in grams.

Group C: Singleton conceived from frozen embryo transfer (IVF/ICSI)

* Neonatal neurobehavior will be measured by Brazelton neonatal behavior assessment scale.
* Neonatal maturity will be represented by the variance of estimated gestational age that determined by new Ballard score.
* Apgar score will be represented by the variance of degree of scores.
* Birth weight will be measured in grams.

Assessment by Brazelton neonatal behavior for group A,Band C

Intervention Type OTHER

* Neonatal neurobehavior will be measured by Brazelton neonatal behavior assessment scale.
* Neonatal maturity will be represented by the variance of estimated gestational age that determined by new Ballard score.
* Apgar score will be represented by the variance of degree of scores.
* Birth weight will be measured in grams.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Assessment by Brazelton neonatal behavior for group A,Band C

* Neonatal neurobehavior will be measured by Brazelton neonatal behavior assessment scale.
* Neonatal maturity will be represented by the variance of estimated gestational age that determined by new Ballard score.
* Apgar score will be represented by the variance of degree of scores.
* Birth weight will be measured in grams.

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Assessment by new ballard score for group A,Band C Assessment infant weight scale for group A,Band C assessment by APGAR score for group A,B and C

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Singleton born through IVF/ICSI (frozen embryo transfer and fresh embryo transfer) after 37 weeks of gestation.
* Singleton whose mothers are aged from 25 to 35 years old and has BMI ranged from 18.5 to 29.

Exclusion Criteria

* Singleton will be excluded from study if one or more of the following is present:

1. vanishing twins (singleton birth where a twin pregnancy recorded at 7 weeks of gestational age (double heart rate at sound)).
2. Preterm singleton.
3. Congenital anomalies
4. Gestational surrogates.
5. Donor oocyte pregnant.
6. Multiple birth.
7. Singleton whose mothers have

* Metabolic diseases (hypertension and diabetes).
* Chronic health issues (asthma and epilepsy).
* Gestational condition (preeclampsia, impaired glucose tolerance, gestational diabetes, anemia and ULT occurrence).
* Placenta previa and placenta accrete.
* Premature rapture of membrane.
* Premature uterine contraction.
* Cervical insufficiency.
* Smoker mother.
Minimum Eligible Age

1 Hour

Maximum Eligible Age

2 Days

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Cairo University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Sally Ashraf Mohammed Askar

Principle investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Faculty of Physical Therapy

Cairo, , Egypt

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

sally ashraf asker, assistant lecture

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Sasker_phd2021

Identifier Type: -

Identifier Source: org_study_id